This receptor is highly expressed in normal and malignant plasma cells and at low levels in subsets of normal immune cells including T-cells, NK cells and B cells which makes SLAMF7 an attractive target for immunotherapy.14, 16 The role of SLAMF7 in the pathogenesis of MM has not been fully elucidated, but data suggest that SLAMF7 mediates MM cell adhesion to bone marrow stromal cells and plays an important role in MM cell survival.15 This evidence concerns the gene SLAMF7 and Miyoshi myopathy.